(Q37964713)

English

Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma

scientific article published on December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gillian M Keating

2

object named as

Gillian M Keating

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Sean T Duggan

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2531-2558

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

https://scigraph.springernature.com/pub.10.2165/11207510-000000000-00000

0 references

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Cardiac safety of liposomal anthracyclines

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Concept and clinical evaluation of carrier-mediated anticancer agents

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Prognostic factors for multiple myeloma in the era of novel agents

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Extending survival with chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Ethics in nanomedicine

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.2165%2F11207510-000000000-00000

21 January 2018

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New advances in ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

British HIV Association guidelines for HIV-associated malignancies 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22141391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11207510-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37964713&oldid=1735107177"